Generic Name and Formulations:
Trifluridine 1%; oph. soln; contains thimerosal.
Indications for VIROPTIC:
Primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex types 1 and 2.
Adults and Children:
<6yrs: not recommended. Do not exceed recommended dose. ≥6yrs: 1 drop every 2hrs while awake; max 9 drops/day. After reepithelialization, 1 drop every 4hrs for 7 days (at least 5 drops/day); max 21 days therapy. Reevaluate if no improvement in 7 days or incomplete reepithelialization in 14 days.
Glaucoma. Pregnancy (Cat.C). Nursing mothers.
Transient ocular burning or stinging, keratopathy, edema, irritation, keratitis sicca, hyperemia, increased intraocular pressure.
Clinical Pain Advisor Articles
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit